Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kazutaka Gomisawa"'
Autor:
Toshiki Futakuchi, Akira Dobashi, Hideka Horiuchi, Hiroto Furuhashi, Hiroaki Matsui, Yuko Hara, Masakuni Kobayashi, Shingo Ono, Naoto Tamai, Kazutaka Gomisawa, Takashi Yamauchi, Machi Suka, Kazuki Sumiyama
Publikováno v:
BMC Gastroenterology, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Background Texture and color enhancement imaging (TXI) enhances the changes in endoscopic features caused by gastric neoplasms, such as redness/whiteness and elevation/depression. This study aimed to demonstrate the effectiveness of TXI in i
Externí odkaz:
https://doaj.org/article/b1169da7d980479696355e2e3b5a7074
Autor:
Takashi Aida, Masashi Tsunematsu, Kenei Furukawa, Koichiro Haruki, Yoshihiro Shirai, Shinji Onda, Yoichi Toyama, Kazutaka Gomisawa, Hiroyuki Takahashi, Toru Ikegami
Publikováno v:
Surgical Case Reports, Vol 7, Iss 1, Pp 1-4 (2021)
Abstract Background The intracystic papillary neoplasm (ICPN) is a newly established disease concept. It has been regarded as a preinvasive neoplastic lesion, similar to intraductal papillary mucinous neoplasm of the pancreas. Limited information is
Externí odkaz:
https://doaj.org/article/adb7616db2504dd5b8bb565841eaa492
Autor:
Hiroyuki Takahashi, Yoshihiro Shirai, Kenei Furukawa, Toru Ikegami, Kazutaka Gomisawa, Yoichi Toyama, Koichiro Haruki, Masashi Tsunematsu, Takashi Aida, Shinji Onda
Publikováno v:
Surgical Case Reports, Vol 7, Iss 1, Pp 1-4 (2021)
Surgical Case Reports
Surgical Case Reports
Background The intracystic papillary neoplasm (ICPN) is a newly established disease concept. It has been regarded as a preinvasive neoplastic lesion, similar to intraductal papillary mucinous neoplasm of the pancreas. Limited information is available
Autor:
Jun Takei, Yasuharu Akasaki, Toshihide Tanaka, Nei Fukasawa, Kazutaka Gomisawa, Mari Satake, Ryosuke Mori, Yohei Yamamoto, Ayaka Oda, Yuko Kamata, Mutsunori Murahashi, Takahiro Fukuda, Masayuki Shimoda, Yuichi Murayama
Publikováno v:
Neuro-Oncology. 24:vii5-vii5
Although immunotherapy has become an attractive approach to cancer treatment in patients with broad types of aggressive tumors, phase III clinical trials of immunotherapy for glioblastoma (GBM) have not achieved extended survival of patients. Dendrit